Milestone Pharmaceuticals reports Q4 EPS (16c), consensus (18c)

As of December 31, 2025, Milestone had cash, cash equivalents, and short-term investments of $106M, compared to $69.7M on December 31, 2024. “We are excited to see that our commercial launch of CARDAMYST and the initial engagement with providers, patients and payers is tracking or exceeding our pre-launch expectations,” said Joseph Oliveto, president and CEO of Milestone Pharmaceuticals (MIST). “Our national sales force was fully deployed within eight weeks of our mid-December approval. Feedback from prescribers supports our belief that there is meaningful demand for a convenient, self-administered option to treat episodes of PSVT, and patient reactions to having CARDAMYST in hand is inspiring.”